{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458269850
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = Fab
| source = o
| target = [[5T4]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 676258-98-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 93T929W6LC
<!-- Chemical data -->
| C=3255 | H=5025 | N=855 | O=1050 | S=18
| molecular_weight = 73.5 kg/mol
}}
'''Naptumomab estafenatox''' (ABR-217620) is a [[Pharmaceutical drug|drug]] being developed for the treatment of various types of [[cancer]] like [[non-small cell lung carcinoma]]<ref>{{cite journal|pmid=19636016|year=2009|last1=Borghaei|first1=H|last2=Alpaugh|first2=K|last3=Hedlund|first3=G|last4=Forsberg|first4=G|last5=Langer|first5=C|last6=Rogatko|first6=A|last7=Hawkins|first7=R|last8=Dueland|first8=S|last9=Lassen|first9=U|title=Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer|volume=27|issue=25|pages=4116â€“23|doi=10.1200/JCO.2008.20.2515|pmc=2734423|journal=Journal of Clinical Oncology}}</ref> and [[renal cell carcinoma]].<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00420888 ClinicalTrials.gov]</ref>

[[File:Fab-superantigen-fusion protein.svg|thumb|left|Schematic image of naptumomab estafenatox.<br />
'''V<sub>H</sub>''', '''V<sub>L</sub>''': variable (antigen binding) domains of antibody fragment<br />
'''C<sub>H</sub>1''', '''C<sub>L</sub>''': constant domains of antibody fragment<br />
'''SAg''': superantigen SEA/E-120]]

==Mechanism of action==
Chemically, it is a [[fusion protein]] consisting of the [[Fragment antigen-binding|antigen-binding fragment]] (Fab) of a [[monoclonal antibody]] with the [[superantigen]] ''staphylococcal enterotoxin A'' (SEA/E-120, "estafenatox").<ref>[http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf WHO Drug Information]</ref> The Fab binds to [[5T4]], an [[antigen]] expressed by various tumor cells, and the superantigen induces an immune response by activating [[T lymphocyte]]s.

==See also==
* [[Nacolomab tafenatox]], a drug with a similar chemical structure and mechanism

==References==
{{reflist}}

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}